Press Releases

alzheimer igc pharma
IGC Receives No objection letter from Health Canada JAN 4. 3023
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act
Read More →
clincloud
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer Disease
Read More →
igc pharma
IGC to Present at the RHK 2022 Disruptive Growth Conference
Read More →
igc pharma
IGC Reports Financial Results for the Quarter Ended September 30, 2022
Read More →
igc-ad1 igc pharma
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
Read More →
igc pharma
IGC Announces Results of its 2022 Annual Stockholders Meeting
Read More →
igc pharma
IGC Reports Financial Results for the Quarter Ended June 30, 2022
Read More →
igc pharma
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022
Read More →
igc-ad1
IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate
Read More →
clincloud
IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders
Read More →
igc pharma
India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits
Read More →
igc pharma
IGC Appoints Claudia Grimaldi to its Board of Directors
Read More →
igc pharma
IGC Reports Financial Results for the December 31, 2021 Quarter
Read More →